Dr. Agarwal's Health Care Limited (NSE:AGARWALEYE)

Market Cap	145.78B +14.8%
Revenue (ttm)	20.80B +21.6%
Net Income	1.33B +59.6%
EPS	4.18 +50.4%
Shares Out	316.96M
PE Ratio	110.04
Forward PE	79.08
Dividend	n/a
Ex-Dividend Date	n/a

Volume	93,540
Open	456.55
Previous Close	459.95
Day's Range	449.10 - 457.15
52-Week Range	345.00 - 568.00
Beta	n/a
Analysts	Buy
Price Target	545.00 (+20.71%)
Earnings Date	May 21, 2026

About Dr. Agarwal's Health Care

Dr. Agarwal's Health Care Limited operates eye hospitals in India and internationally. It offers cataract surgeries, such as small incision cataract surgery, phacoemulsification, robotic cataract surgery, and glued intraocular lens treatments; and refractive surgeries, including surgical procedures to correct the refractive error of the eye to get rid of or reduce dependence on glasses and contact lens. The company also provides surgical retinal treatments, corneal transplantation and pinhole pupilloplasty, oculoplasty, and surgeries for the tr...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 2010
• Country: India
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: AGARWALEYE

Financial Performance

In fiscal year 2026, Dr. Agarwal's Health Care's revenue was 20.80 billion, an increase of 21.57% compared to the previous year's 17.11 billion. Earnings were 1.33 billion, an increase of 59.59%.

Analyst Summary

According to 5 analysts, the average rating for AGARWALEYE stock is "Buy." The 12-month stock price target is ₹545.00, which is an increase of 20.71% from the latest price.

Price Target

₹545.00

(20.71% upside)

Analyst Consensus: Buy